Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
Endocrinology 149 (5), 20382047
Participants were eligible if we had the following data available at the start of treatment (day 0) and at the follow-up after one year (365 14 days): Before treatment initiation: sex, age (years), body weight (kg), waist circumference (cm), height (cm), body mass index (BMI), systolic and diastolic blood pressure, heart rate, and Edmonton Obesity Staging System (EOSS) score
Introduction Obese-range body mass index (BMI) is an established risk factor for breast cancer recurrence, shortened breast cancerspecific survival, and overall survival
Secondary applications with emerging evidence include wound healing in patients with non-healing tissue, hair follicle stimulation, and early-stage research into cardiac recovery effects following the 2026 human trial data on Thymosin Beta-4
Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR
US$ 20.52
US$ 22.81
US$ 21.25
US$ 20.09
US$ 20.48
US$ 25.67
